









Markets
/
Stocks
/
nasdaq-celc
/

Celcuity Inc

CELC

View Detailed Chart

38.500USD

+1.710+4.65%

Close 07/29, 16:00（ET）Quotes delayed by 15 min

1.46BMarket Cap

LossP/E TTM



Celcuity Inc

38.500

+1.710+4.65%

Overview Company Financials

Financials

Intraday

30m

Today

+4.65%

5 Days

+176.18%

1 Month

+207.02%

6 Months

+235.95%

Year to Date

+194.12%

1 Year

+114.48%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 8 analysts

BUY

Current Rating

55.857

Target Price

51.83%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Celcuity Inc

CELC

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(0)

Buy(10)

Indicators

Sell(1)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

4.711

Buy

RSI(14)

95.527

Overbought

STOCH(KDJ)(9,3,3)

66.489

Buy

ATR(14)

3.498

High Vlolatility

CCI(14)

228.047

Overbought

Williams %R

23.949

Buy

TRIX(12,20)

2.172

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

23.432

Buy

MA10

18.584

Buy

MA20

16.009

Buy

MA50

13.416

Buy

MA100

11.819

Buy

MA200

12.437

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

Ticker SymbolCELC

CompanyCelcuity Inc

CEOMr. Brian F. Sullivan

Websitehttps://www.celcuity.com/